According to recent research titled ‘GLOBAL INJECTABLE DRUG DELIVERY MARKET 2019-2027’, available with Market Study Report, global injectable drug delivery market is expected to showcase a yearly growth rate of 8.67% during 2019-2027.
 

Expanding elderly population, technological advancements, and rising prevalence of autoimmune disorders the are major factors stimulating the global injectable drug delivery market growth. Moreover, emergence of innovative injectable systems will present new growth opportunities. On the other hand, high manufacturing cost will negatively impact business outlook over the projected timeline, cites the study.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2519226/
 

Based on device type, worldwide injectable delivery market is categorized into pen injector, needle-free injector, auto-injector, prefilled syringe. Considering route of administration, the industry is split into subcutaneous, intravenous, intramuscular, and others. Speaking of the end-use spectrum, the market is classified into ambulatory care, clinics/physician offices, home-based, hospital, and others.
 

As per the regional analysis, global injectable drug delivery market is segmented into North America, Europe, Latin America, Asia-Pacific, and Middle East & Africa. Asia Pacific is touted to grow exponentially over the forecast timeline on account of factors such as presence of a large geriatric populace, improving life expectancy, and rising disposable income in the region. Increased pervasiveness of chronic ailments like CVDs, diabetes, and auto-immune disorders are further strengthening the product demand.
 

Leading industry players are Ypsomed Holding, West Pharmaceutical Services, Inc., Teva Pharmaceutical Industries Ltd., Terumo Corp., Schott AG, Sanofi S.A., Pfizer, Inc., Novo Nordik A/S, Novartis AG, Injex, Gerresheimer AG, Eli Lilly and Company, Elcam Medical, Becton, Dickinson and Company, and Baxter AG.